Treanda is a brand name of bendamustine, approved by the FDA in the following formulation(s):
TREANDA (bendamustine hydrochloride - powder; iv (infusion))
Manufacturer: CEPHALON
Approval date: March 20, 2008
Strength(s): 100MG/VIAL [RLD]
Manufacturer: CEPHALON
Approval date: May 1, 2009
Strength(s): 25MG/VIAL [RLD]
Has a generic version of Treanda been approved?
No. There is currently no therapeutically equivalent version of Treanda available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Treanda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Treanda.
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 31, 2011 - INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
- March 20, 2013 - NEW CHEMICAL ENTITY
- March 20, 2015 - ORPHAN DRUG EXCLUSIVITY
See also...
- Treanda Consumer Information (Drugs.com)
- Treanda Consumer Information (Wolters Kluwer)
- Treanda Consumer Information (Cerner Multum)
- Treanda Advanced Consumer Information (Micromedex)
- Bendamustine Consumer Information (Wolters Kluwer)
- Bendamustine Consumer Information (Cerner Multum)
- Bendamustine Intravenous Advanced Consumer Information (Micromedex)
